.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Abstract Talk
AT 20

The pragmatic, multi-center, three-arm, partially randomized HEVACC trial – heterologous SARS-CoV-2 vaccination with ChAdOx-1 and BNT162b2

Appointment

Date: 5th May 2023

Time: 03:00 p.m. – 03:15 p.m.

Talk time: 10 Min.

Discussion time: 5 Min.

Location / Stream:

Sala Biała

Session

Vaccines I

Topic

Vaccines

Authors

Annika Rössler (Innsbruck / AT), Zoltan Banki (Innsbruck / AT), Jose Mateus (La Jolla, CA / US), Alba Grifoni (La Jolla, CA / US), Alessandro Sette (La Jolla, CA / US), Viviana Simon (New York, NY / US), Hanno Ulmer (Innsbruck / AT), Dr. Wegene Borena (Innsbruck / AT), HEVACC Study Group (Innsbruck / AT), Florian Krammer (New York, NY / US), Prof. Dr. Dorothee von Laer (Innsbruck / AT), Daniela Weiskopf (La Jolla, CA / US), Dr. Janine Kimpel (Innsbruck / AT)